Anabela Cardoso

3.1k total citations
18 papers, 481 citations indexed

About

Anabela Cardoso is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, Anabela Cardoso has authored 18 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 8 papers in Genetics and 8 papers in Hematology. Recurrent topics in Anabela Cardoso's work include Rheumatoid Arthritis Research and Therapies (11 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Anabela Cardoso is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (11 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Anabela Cardoso collaborates with scholars based in United States, Japan and United Kingdom. Anabela Cardoso's co-authors include Gerd R Burmester, Chadi Saifan, Maher Issa, Peter C. Taylor, Terence Rooney, Tsutomu Takeuchi, Chad D. Walls, Mark C. Genovese, Jeffrey R. Curtis and Sarah Witt and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Allergy and Clinical Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Anabela Cardoso

15 papers receiving 471 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anabela Cardoso United States 8 268 117 93 78 69 18 481
Nicola Farina Italy 13 128 0.5× 65 0.6× 169 1.8× 70 0.9× 103 1.5× 30 459
Martin Feuchtenberger Germany 12 173 0.6× 73 0.6× 66 0.7× 24 0.3× 55 0.8× 42 396
Laura Bogliolo Italy 10 200 0.7× 34 0.3× 194 2.1× 47 0.6× 125 1.8× 22 506
T. Klopsch Germany 6 444 1.7× 180 1.5× 54 0.6× 24 0.3× 20 0.3× 12 597
Jeffrey B. Shiroky Canada 12 397 1.5× 142 1.2× 22 0.2× 76 1.0× 26 0.4× 16 669
Д. Е. Каратеев Russia 11 436 1.6× 147 1.3× 32 0.3× 75 1.0× 15 0.2× 174 667
Corinne Duguet France 6 154 0.6× 223 1.9× 27 0.3× 131 1.7× 31 0.4× 7 530
Ani John United States 14 416 1.6× 166 1.4× 19 0.2× 46 0.6× 23 0.3× 30 575
Camelia Doina Vrabie Romania 9 281 1.0× 57 0.5× 12 0.1× 44 0.6× 32 0.5× 27 517
Ilenia Di Cola Italy 7 184 0.7× 109 0.9× 22 0.2× 39 0.5× 12 0.2× 24 397

Countries citing papers authored by Anabela Cardoso

Since Specialization
Citations

This map shows the geographic impact of Anabela Cardoso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anabela Cardoso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anabela Cardoso more than expected).

Fields of papers citing papers by Anabela Cardoso

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anabela Cardoso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anabela Cardoso. The network helps show where Anabela Cardoso may publish in the future.

Co-authorship network of co-authors of Anabela Cardoso

This figure shows the co-authorship network connecting the top 25 collaborators of Anabela Cardoso. A scholar is included among the top collaborators of Anabela Cardoso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anabela Cardoso. Anabela Cardoso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Capolino, Gérard‐André, Anabela Cardoso, Bilal Akin, et al.. (2023). Committees. 9–10. 1 indexed citations
2.
Pope, Janet, Yvonne Lee, Jeffrey R. Curtis, et al.. (2021). Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib. ACR Open Rheumatology. 4(3). 254–258. 3 indexed citations
3.
Genovese, Mark C., Josef S Smolen, Tsutomu Takeuchi, et al.. (2020). Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. The Lancet Rheumatology. 2(6). e347–e357. 55 indexed citations
4.
Sims, Jonathan T., Venkatesh Krishnan, Sarah Engle, et al.. (2020). Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. Journal of Allergy and Clinical Immunology. 147(1). 107–111. 107 indexed citations
5.
Nowell, W. Benjamin, Kelly Gavigan, Zhihong Cai, et al.. (2020). PARE0026 WHICH PATIENT-REPORTED OUTCOMES DO RHEUMATOLOGY PATIENTS FIND IMPORTANT TO TRACK DIGITALLY? A REAL-WORLD LONGITUDINAL STUDY IN ARTHRITISPOWER. Annals of the Rheumatic Diseases. 79. 1298–1299. 1 indexed citations
6.
Smolen, Josef S, Li Xie, Bochao Jia, et al.. (2020). Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study . Lara D. Veeken. 60(5). 2256–2266. 17 indexed citations
7.
Smolen, Josef S, Lechun Xie, Bochao Jia, et al.. (2020). SAT0152 EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY. Annals of the Rheumatic Diseases. 79. 1016–1016. 2 indexed citations
8.
Michaud, Kaleb, Janet Pope, Mart van de Laar, et al.. (2020). Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. Arthritis Care & Research. 73(11). 1606–1616. 47 indexed citations
9.
Kay, Jonathan, Masayoshi Harigai, Christina Dickson, et al.. (2020). Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 6(3). e001370–e001370. 30 indexed citations
10.
Fleischmann, Roy, Michael Schiff, Tore K Kvien, et al.. (2019). THU0075 EARLY VERSUS DELAYED START OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3 TRIAL OF PATIENTS NAÏVE TO METHOTREXATE TREATMENT. Annals of the Rheumatic Diseases. 78. 306–307. 1 indexed citations
11.
Genovese, Mark C., Josef S Smolen, Tsutomu Takeuchi, et al.. (2019). THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. Annals of the Rheumatic Diseases. 78. 308–309. 21 indexed citations
12.
Taylor, Peter C., Michael E. Weinblatt, Gerd R Burmester, et al.. (2019). Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis & Rheumatology. 71(7). 1042–1055. 134 indexed citations
13.
Genovese, Mark C., Brett Hauber, W. Benjamin Nowell, et al.. (2019). Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. Rheumatology and Therapy. 6(3). 461–471. 58 indexed citations
14.
Ruperto, Nicolino, Daniel J. Lovell, D. Kingsbury, et al.. (2015). FRI0502 Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis. Annals of the Rheumatic Diseases. 74. 610–611.
15.
16.
Cardoso, Anabela, et al.. (2011). Avaliação clínica não-invasiva de disfagia no AVC – Revisão sistemática. Revista de Enfermagem Referência. III Série(nº 5). 135–143. 2 indexed citations
17.
Cardoso, Anabela, et al.. (2011). Avaliação clínica não-invasiva de disfagia no AVC: Revisão sistemática Evaluación clínica no invasiva de disfagia en el ACV: Revisión sistemática Non-invasive dysphagia screening for stroke survivors: Systematic review. SHILAP Revista de lepidopterología. 1 indexed citations
18.
Colombel, J.F., Remo Panaccione, William J. Sandborn, et al.. (2008). P011 GLOBAL SAFETY OF ADALIMUMAB IN CROHN'S DISEASE CLINICAL TRIALS. 2(1). 8–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicola Farina Breakdown of academic impact, for papers by Martin Feuchtenberger Breakdown of academic impact, for papers by Laura Bogliolo Breakdown of academic impact, for papers by T. Klopsch Breakdown of academic impact, for papers by Jeffrey B. Shiroky Breakdown of academic impact, for papers by Д. Е. Каратеев Breakdown of academic impact, for papers by Corinne Duguet Breakdown of academic impact, for papers by Ani John Breakdown of academic impact, for papers by Camelia Doina Vrabie Breakdown of academic impact, for papers by Ilenia Di Cola
Rankless by CCL
2026